Aardvark Therapeutics, Inc. Common Stock
Aardvark Therapeutics, Inc. Common Stock (AARD) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
aard · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Aardvark Therapeutics, Inc. Common Stock (AARD) measures how much investors pay for each dollar of the company's trailing earnings. AARD's current PE ratio of N/A is calculated by dividing its stock price of $3.59 by its TTM earnings per share of -$3.20.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2022 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Aardvark Therapeutics, Inc. Common StockYou AARD | $78M | N/A | — | -$3.20 |
 Assembly Biosciences, Inc. ASMB | $358M | N/A | — | -$0.55 |
 Avalo Therapeutics, Inc. AVTX | $144M | N/A | — | -$5.84 |
 Caribou Biosciences, Inc. CRBU | $182M | N/A | — | -$1.59 |
 Enanta Pharmaceuticals, Inc. ENTA | $257M | N/A | — | -$3.84 |
 Eupraxia Pharmaceuticals Inc. EPRX | $201M | N/A | — | -$1.35 |
 Foghorn Therapeutics Inc. FHTX | $218M | N/A | — | -$1.18 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-2.64 | — | |
2024-12-31 FY2024 | — | $-0.95 | — | |
2023-12-31 FY2023 | — | $-0.34 | — | |
2022-12-31 FY2022 | — | $-0.63 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Aardvark Therapeutics, Inc. Common Stock (AARD) measures how much investors pay for each dollar of the company's trailing earnings. AARD's current PE ratio of N/A is calculated by dividing its stock price of $3.59 by its TTM earnings per share of -$3.20.
Frequently asked questions
AARD pe ratio · 6 questionsAARD's current PE ratio is N/A as of 2026-06-08, based on a stock price of $3.59 and TTM EPS of -$3.20. Data sourced from Financial Modeling Prep via AARD's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Aardvark Therapeutics, Inc. Common Stock SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08